In this live News Network from the Revolutionizing Atopic Dermatitis (RAD) 2023 Annual Meeting in Washington, DC, this month, a trio of dermatologists reflected on the first year of marketed use of ruxolitinib cream (Opzelura) for the treatment of vitiligo in patients aged 12 years and older.
Raj Chovatiya, MD, PhD, assistant professor of dermatology and director of The Center for Eczema and Itch and medical director of clinical trials at the Northwestern University Feinberg School of Medicine in Chicago, IL, discussed the utility of ruxolitinib cream in real-world patients following its historic FDA approval last year, as well as the state of disease monitoring and continued care.
Afterward, he spoke with David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.
Lastly, Chovatiya was joined by Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology for Rady Children's Hospital-San Diego, as well as professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine, to discuss how ruxolinitib cream altered the management of pediatric and adolescent vitiligo patients ≥12 years old, as well as pediatric-specific considerations for those who may be eligible for JAK inhibitor treatment.
Watch the full video series above.